Contact us Demo our platform

Metabolon @

BiotechX Europe 2025

Dates: 6th – 8th October 2025
Location: Basel, Switzerland
Link to Official Event Website: https://www.terrapinn.com/conference/biotechx/

Join Metabolon at BiotechX Europe 2025

Metabolon is attending the 2025 BiotechX Europe Congress, Europe’s largest congress for diagnostics, precision medicine, and digital transformation in biopharma. This premier event brings together scientists, clinicians, regulators, and technology leaders to drive innovation at the intersection of multi-omics, AI, and healthcare delivery.

You will find Metabolon’s team in Booth 728. As leaders in metabolomics and multiomics integration, we’re excited to engage with global biotech professionals driving the future of drug discovery, diagnostics, and data-driven healthcare. 

Visit us at Messe Basel to explore how metabolomics delivers actionable insights that accelerate therapeutic development and precision health strategies across a wide range of disease areas. 

Key Themes at BiotechX Europe 2025

BiotechX Europe 2025 will showcase innovative research and emerging technologies across key focus areas such as:

• Multi-Omics for Clinical Translation — Integration of genomics, proteomics, metabolomics, and transcriptomics to guide therapeutic development and clinical decision-making.
• AI & Data Science in Life Sciences — Application of machine learning, predictive analytics, and digital biomarkers to drug discovery and diagnostics.
• Next-Generation Diagnostics — Advancements in non-invasive and molecular diagnostics, companion diagnostics, and biomarker panels.
• Personalized Medicine & Patient-Centricity — Strategies for individualized therapy and real-world data implementation in clinical care.
• Metabolomics in Precision Health — The role of metabolism and biomarkers in advancing disease understanding, treatment response, and real-time biological insights.

👉 View Full Agenda

Metabolomics plays a critical role across these themes by enabling a dynamic understanding of health and disease states, translating biological complexity into meaningful diagnostics and targeted therapeutic strategies.

The Role of Metabolomics in Precision Medicine & Omics Integration

As the biochemical layer most closely tied to phenotype, metabolomics enables researchers to move beyond genomics and transcriptomics to understand functional biology in real time. 

Metabolon supports biotech and pharmaceutical innovators by: 

  • Revealing metabolic pathways driving disease mechanisms 
  • Identifying novel biomarkers for efficacy, safety, and response 
  • Supporting target validation and mechanism-of-action studies 
  • Enhancing patient stratification and companion diagnostics 
  • Enabling early detection and progression monitoring 

Metabolomics plays a critical role in reducing development risk, accelerating timelines, and maximizing translational insight from discovery through clinical trials. 

Find out more:

Explore sessions aligned with Metabolon’s areas of expertise, including: 

  • Multiomics & Biomarker Discovery 
    Advances in integrating metabolomics with genomics, proteomics, and microbiome data to uncover biomarkers with functional impact. 
  • Clinical & Translational Research 
    Case studies demonstrating the power of metabolomics in stratifying patient populations, monitoring therapeutic efficacy, and identifying metabolic drivers of disease. 
  • AI in Drug Development 
    How advanced analytics are reshaping interpretation of complex multiomic data to inform faster and more accurate decision-making. 

Don’t miss out on our poster:  

Poster number: 29
Title: Advancing Drug Discovery through Metabolomics-Driven Multiomics Integration 

 View Full Agenda → 

Why Visiting Metabolon’s Booth at BiotechX Europe 2025

Whether you’re focused on preclinical discovery or clinical development, the Metabolon team is here to help you harness the full potential of metabolomics. 

At our booth, you can: 

  • Discuss your research or clinical objectives with our scientific team 
  • Learn how our global metabolomics platform delivers unmatched data quality and biological interpretation 
  • Explore real-world case studies across oncology, neurology, immunology, gastroenterology, and more 
  • Discover how multiomics integration is driving a new era of personalized medicine 

We invite you to schedule a meeting or stop by to see how Metabolon can accelerate your science. 

Visit us at Booth 728 to discover how our biology-first approach reveals novel, clinically actionable biomarkers that drive precision medicine forward.

Meet Metabolon’s Team at BiotechX Europe 2025

Kieran Jones, Strategic Account Manager, International. 

With a scientific background in immunology and clinical development, he spent several years in pharma and CDMO roles at UCB and Lonza before transitioning into commercial. At Metabolon, he helps biopharma partners integrate metabolomics into their drug development, clinical, and manufacturing programs to accelerate decision-making and biomarker-driven strategy. 

Joe Foster, Director of Strategic Products. 

With 15+ years of bioinformatics expertise across genomics, proteomics, lipidomics, and metabolomics, Joe currently the roadmap for the Integrated Bioinformatics Platform (IBP)and develops Bioinformatics Professional Services to accelerate insights through scalable multiomics solutions. Formerly with Affymetrix, Thermo Fisher, and DNAnexus, Joe is passionate about advancing the idea that multiomics without metabolomics only scratches the surface of biological complexity. 

With a PhD in Bioinformatics from the University of Cambridge and the European Bioinformatics Institute, Joe combines a strong scientific foundation with a practical, results-oriented approach to integrating metabolomics data into the broader multiomics landscape. 

Joseph McGinley, Senior Bioinformatician.

With seven years of experience applying bioinformatics methods to answer biological questions. Joseph is a member of Metabolon’s bioinformatics team and currently works on the development of Metabolon’s visualization platform along with providing bioinformatics support for internal research initiatives.

Schedule a meeting with our team using the contact form on this page, to explore how metabolomics can inform your research goals.

Quick Links to Learn More About BioTechX 

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

P7 Homepage Resource Categories
  • All
  • Case Studies (92)
  • Videos (90)
  • eBooks (47)
  • Posters (20)
  • Product Literature (13)
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.